When was Stelis Biosource founded?

Stelis Biosource was founded in 2012.

Where is Stelis Biosource located?

Stelis Biosource is headquartered in Bengaluru, India. It is registered at Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Thane, Maharashtra, India, 400703.

Which legal entities is Stelis Biosource associated with?

Stelis Biosource is associated with ONESOURCE SPECIALTY PHARMA LIMITED.

How many employees does Stelis Biosource have?

As of Aug 31, 2025, the latest employee count at Stelis Biosource is 1513.

Is Stelis Biosource a funded company?

Stelis Biosource is a funded company, having raised a total of $195M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round.

How much is Stelis Biosource worth?

The latest valuation of Stelis Biosource is $***** as of Apr 07, 2021.

When was the latest funding round of Stelis Biosource?

Stelis Biosource's latest funding was a $***** Series C round on Mar 19, 2021, with participation from 5 investors.

What is the annual revenue of Stelis Biosource?

Annual revenue of Stelis Biosource is more than ₹1,000 Cr as on Mar 31, 2026

Where does Stelis Biosource rank among its competitors?

Stelis Biosource ranks 16th amongst 374 active competitors, of which 41 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Acclinate, which secured $3.5M in Feb, 2026.

Who are the top competitors of Stelis Biosource?

Stelis Biosource's top competitors include Novartis, Catalent and Surrozen. Among them, Acclinate secured the most recent funding round in February, 2026.

Stelis Biosource - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

CDMO providing solutions for end-to-end biopharmaceutical manufacturing needs. It offers services such as process development & scale- up, analytical development and cGMP manufacturing. The process development services include upstream development & scale up services in both microbial & mammalian expression systems, downstream processes such as chromatography, filtration, precipitation/crystallization, virus removal & inactivation and formulation development such as injectable in vials, prefilled syringes & cartridges.

Website: stelisbiosource.com
Part Of
Registered Address: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Thane, Maharashtra, India, 400703

Key Metrics

Founded Year

2012

Location

Bengaluru, India

Stage

Series C

Total Funding

$195M in 2 rounds

Latest Funding Round

Series C, Mar 19, 2021, $*****

Post Money Valuation

$***** as on Apr 07, 2021

Investors

TPG & 4 more

Ranked

16^th among 374 active competitors

Annual Revenue

₹1,000+ Cr as on Mar 31, 2026

Employee Count

1,513 as on Aug 31, 2025

Similar Companies

Novartis & 427 more

View Stelis Biosource's full profile

Stelis Biosource is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ONESOURCE SPECIALTY PHARMA LIMITED CIN: L74140MH2007PLC432497 , India, Active	Jun 12, 2007	₹1,000+ Cr (As on Mar 31, 2026)	1672 (As on Mar 01, 2026)

Stelis Biosource has raised a total funding of $195M over 2 rounds. Its latest funding round was a Series C round on Mar 19, 2021 for $*****. 5 investors participated in its latest round. Stelis Biosource has 5 institutional investors.

Here is the list of recent funding rounds of Stelis Biosource:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 19, 2021	2499380	Series C	6658345	9889863	5881785	4744813

Access funding benchmarks and valuations. Sign up today!

View details of Stelis Biosource's funding rounds and investors

The founders of Stelis Biosource is Arun Kumar.

Here are the details of Stelis Biosource's key team members:

Arun Kumar: Founder & Director of Stelis Biosource.

Stelis Biosource's Board of Directors

Stelis Biosource's board has 8 active members. Mahadevan Narayanamoni, Aditya Puri, Ankur Thadani, Kannan Pudhucode, Arun Kumar Pillai, Vineeta Raina, Sudhir Krishna Kanchan and Adayapalam Kumaraswamy Viswanathan are independent board members.

Here is the list of Stelis Biosource's board of directors:

Name	Type	Representing	Status	Duration
Mahadevan Narayanamoni	Independent board member	-	Current	5y 6m
y{qzmtk	Independent board member	-	Current	7y 7m
apboxtf	Independent board member	-	Current	2y 9m
gjwzxnr	Independent board member	-	Current	8y 1m
cigwnno	Independent board member	-	Current	2y 2m
loyagop	Independent board member	-	Past	8y 8m
wjcgylc	Independent board member	-	Past	3y 9m
btvtftm	Independent board member	-	Past	4y 5m
qi{weqx	Independent board member	-	Past	3y 1m
ejozfmi	Independent board member	-	Past	6y 2m
qdprjqn	Independent board member	-	Past	8y 4m
ioekhzt	Independent board member	-	Past	9y 2m
doeudzp	Independent board member	-	Past	5y 2m
{yumbmk	Independent board member	-	Past	3y 9m
quzjbgj	Independent board member	-	Past	5y 6m
yccpzgb	Independent board member	-	Past	4y 3m
btygaur	Independent board member	-	Past	9y 6m
terntms	Independent board member	-	Past	2y 7m
w{aneto	Independent board member	-	Past	6y 6m
suzqglc	Independent board member	-	Past	8y 3m
olmkofe	Independent board member	-	Past	7y 3m

View details of Stelis Biosource's Founder profiles and Board Members

Stelis Biosource's employee count trend

Stelis Biosource has 1,513 employees as of Aug 25. The total employee count is 178.0% more than what it was in Aug 24. Here is Stelis Biosource's employee count trend over the years:

Employee count trend for Stelis Biosource

Uncover Stelis Biosource's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Stelis Biosource include Novartis, Catalent and Surrozen. Here is the list of Top 10 competitors of Stelis Biosource, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
2nd	Catalent 2007, Somerset (United States), Acquired	Provider of development, manufacturing, and packaging solutions for medicines and supplements	-	Aisling Capital, JPMorgan Chase & 4 others	68/100
3rd	Surrozen 2016, San Francisco (United States), Public	Pioneering targeted regenerative antibodies to repair tissue and restore organ function	$133M	The Column Group, Horizons Ventures & 13 others	59/100
4th	Acclinate 2020, Birmingham (United States), Series A	Provider of clinical trial services to biopharma sector	$15.5M	Cencora, Alabama Launchpad & 7 others	55/100
5th	Curia 1991, Albany (United States), Acquired	Provider of drug research & development, testing, and consulting services	-	HarbourVest Partners, Thecarlylegroup.fr & 6 others	53/100
6th	WuXi Biologics 2008, Shanghai (China), Public	Developer and manufacturer for protein therapeutics	-	Pivotal bioVenture Partners, HongShan & 3 others	52/100
7th	Sunflower Therapeutics 2018, Hingham (United States), Series A	Provider of drug development & research services for multiple therapeutic areas	$5.64M	NIAID, Clear Current Capital & 3 others	52/100
8th	Ventus Therapeutics 2019, Boston (United States), Series C	Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment	$300M	RA Capital Management, Versant Ventures & 10 others	51/100
9th	BioFactura 2004, Frederick (United States), Series B	Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs	$7.8M	Wilson Sonsini Goodrich & Rosati, UVM Health ... & 2 others	51/100
10th	TCI 1980, Taipei (Taiwan), Public	Manufacturer of functional foods and dietary supplements	-	JAFCO Asia, Japan Asia Investment	49/100
16th	Stelis Biosource 2012, Bengaluru (India), Series C	CDMO providing solutions for end-to-end biopharmaceutical manufacturing needs	$195M	Think Investments, Mankekar Family Office ... & 3 others	45/100